论文部分内容阅读
目的:观察活血化痰方治疗大鼠非酒精性脂肪肝模型生化指标的影响。方法:以高脂饲料喂养6周建立非酒精性脂肪肝病大鼠模型,随机分为正常组,模型组,活血化痰方高、低剂量组,罗格列酮高、低剂量组6组,分别给予生理盐水10 mL·kg-1·d-1,活血化痰方生药38.5,19.25 g·kg-1·d-1,罗格列酮10,5 mg·kg-1·d-1,给药6周。实验结束时,检测大鼠基本生化指标,取肝脏组织进行病理检测。结果:活血化痰方高、低剂量组ALT水平明显降低,治疗效果优于罗格列酮和模型组[(50.7±12.2)(41.3±9.9)(66.3±29.1)(56.9±14.2)(71.3±25.9)U.L-1,P<0.05],活血化痰方高、低剂量组均能显著降低血清总胆固醇(TC)水平[(1.3±0.3)(1.5±0.4)(2.6±1.1)mmol·L-1,P<0.01]和甘油三酯(TG)水平[(0.3±0.2)(0.4±0.2)(0.5±0.2)mmol·L-1,P<0.05],高剂量组能明显降低血糖(GLU)水平[(9.0±1.3)(11.4±2.0)mmol·L-1,P<0.01],活血化痰方和罗格列酮显著改善血液流变学各项指标(P<0.05),且活血化痰方疗效整体优于罗格列酮组,活血化痰方高剂量组也可明显降低模型动物肝脏中TG[(0.73±0.16)(0.81±0.22)(0.57±0.11)(1.06±0.33)mmol·mg-1,P<0.05]和游离脂肪酸(FFA)[(1.77±0.29)(1.66±0.44)(2.04±0.27)μmol·mg-1,P<0.05]。结论:活血化痰方能够从改善肝功能、调节血脂代谢等多个方面改善非酒精性脂肪肝的病理状态。
Objective: To observe the effect of Huoxue Huatan Fang on biochemical indexes of non-alcoholic fatty liver in rats. Methods: A rat model of nonalcoholic fatty liver disease was established by feeding with high-fat diet for 6 weeks. The rats were randomly divided into normal group, model group, high-dose and low-dose group of Huoxuehuatan, high and low dose of rosiglitazone group, The rats were treated with 10 mL · kg-1 · d-1 of normal saline, 38.5 and 19.25 g · kg-1 · d-1 of Huoxue Huatan Fang, 10,5 mg · kg-1 · d-1 of rosiglitazone, Administered for 6 weeks. At the end of the experiment, the basic biochemical indexes of rats were detected and the liver tissues were taken for pathological examination. Results: The levels of ALT in high and low dose of Huoxue Huatan Fang group were significantly lower than those in the model group [(50.7 ± 12.2) (41.3 ± 9.9) (66.3 ± 29.1) and (56.3 ± 14.2), respectively (1.3 ± 0.3) (1.5 ± 0.4) and (2.6 ± 1.1) mmol · L-1 in the high and low dose groups (P <0.05) L-1, P <0.01] and triglyceride (TG) (0.3 ± 0.2) (0.4 ± 0.2) (0.5 ± 0.2) mmol·L-1, P <0.05] (P0.01), and the indexes of GLU (9.0 ± 1.3) (11.4 ± 2.0) mmol·L-1, P <0.01]. The indexes of hemorrheology were significantly improved The curative effect of Huoxue Huatan Fang was better than that of rosiglitazone group. The high dose of Huoxue Huatan Fang group also significantly reduced TG (0.73 ± 0.16) (0.81 ± 0.22) (0.57 ± 0.11) (1.06 ± 0.33) mmol · mg-1, P <0.05] and free fatty acid (FFA) [(1.77 ± 0.29) vs 1.66 ± 0.44 (2.04 ± 0.27) μmol · mg-1, P <0.05; Conclusion: Huoxue Huatan prescription can improve the pathological state of nonalcoholic fatty liver from many aspects such as improving liver function and regulating blood lipid metabolism.